Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 244

1.

Biobanks in Horizon 2020: sustainability and attractive perspectives.

Kinkorová J, Topolčan O.

EPMA J. 2018 Nov 23;9(4):345-353. doi: 10.1007/s13167-018-0153-7. eCollection 2018 Dec. Review.

2.

The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line.

Fiala O, Hosek P, Sorejs O, Liska V, Buchler T, Poprach A, Kucera R, Topolcan O, Sedivcova M, Finek J.

J Cancer. 2018 Oct 20;9(22):4255-4262. doi: 10.7150/jca.26217. eCollection 2018.

3.

One-step nucleic acid amplification vs ultrastaging in the detection of sentinel lymph node metastasis in endometrial cancer patients.

Kosťun J, Pešta M, Sláma J, Slunéčko R, Vlasák P, Bouda J, Novotný Z, Topolčan O, Kučera R, Kulda V, Houfková K, Berezovskiy D, Bartáková A, Presl J.

J Surg Oncol. 2019 Mar;119(3):361-369. doi: 10.1002/jso.25322. Epub 2018 Dec 3.

PMID:
30508294
4.

Can the One-Step Nucleic Acid Amplification method of lymph nodes examination make the staging of pulmonary tumours more precise?

Vodička J, Vejvodová Š, Pešta M, Mukenšnabl P, Špidlen V, Kulda V, Houfková K, Topolčan O.

Rozhl Chir. 2018 Summer;97(8):373-378.

PMID:
30441990
5.

PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study.

Svobodova S, Karlikova M, Topolcan O, Pecen L, Pestova M, Kott O, Treska V, Slouka D, Kucera R.

In Vivo. 2018 Nov-Dec;32(6):1551-1554. doi: 10.21873/invivo.11413.

6.

An Assessment of Novel Biomarkers in Bone Metastatic Disease Using Multiplex Measurement and Multivariate Analysis.

Windrichova J, Kucera R, Fuchsova R, Topolcan O, Fiala O, Svobodova J, Finek J, Slipkova D.

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818807466. doi: 10.1177/1533033818807466.

7.

Portal Vein Embolization (PVE) Versus PVE with Haematopoietic Stem Cell Application in Patients with Primarily Non-resectable Colorectal Liver Metastases.

Treska V, Fichtl J, Ludvik J, Bruha J, Liska V, Treskova I, Kucera R, Topolcan O, Lysak D, Skalicky T, Ferda J.

Anticancer Res. 2018 Sep;38(9):5531-5537. doi: 10.21873/anticanres.12888.

PMID:
30194213
8.

Prodrug suicide gene therapy for cancer targeted intracellular by mesenchymal stem cell exosomes.

Altanerova U, Jakubechova J, Benejova K, Priscakova P, Pesta M, Pitule P, Topolcan O, Kausitz J, Zduriencikova M, Repiska V, Altaner C.

Int J Cancer. 2019 Feb 15;144(4):897-908. doi: 10.1002/ijc.31792. Epub 2018 Sep 27.

PMID:
30098225
9.

OPG, OPN, EGF and VEGF Levels at Individual Breslow Score Stages in Malignant Melanoma.

Treskova I, Topolcan O, Windrichova J, Simanek V, Slouka D, Treska V, Kucera R.

Anticancer Res. 2018 Aug;38(8):4907-4911. doi: 10.21873/anticanres.12806.

PMID:
30061268
10.

Stability of total prostate-specific antigen and free prostate-specific antigen after 10 years' storage.

Simanek V, Topolcan O, Karlikova M, Dolejsova O, Fuchsova R, Kinkorova J, Slouka D, Kucera R.

Int J Biol Markers. 2018 Jul 27:1724600818789414. doi: 10.1177/1724600818789414. [Epub ahead of print]

PMID:
30049237
11.

The Ability of Prostate Health Index (PHI) to Predict Gleason Score in Patients With Prostate Cancer and Discriminate Patients Between Gleason Score 6 and Gleason Score Higher Than 6-A Study on 320 Patients After Radical Prostatectomy.

Dolejsova O, Kucera R, Fuchsova R, Topolcan O, Svobodova H, Hes O, Eret V, Pecen L, Hora M.

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818787377. doi: 10.1177/1533033818787377.

12.

Detection and Quantification of Carbohydrate-Deficient Transferrin by MALDI-Compatible Protein Chips Prepared by Ambient Ion Soft Landing.

Darebna P, Spicka J, Kucera R, Topolcan O, Navratilova E, Ruzicka V, Volny M, Novak P, Pompach P.

Clin Chem. 2018 Sep;64(9):1319-1326. doi: 10.1373/clinchem.2017.285452. Epub 2018 Jul 12.

PMID:
30002097
13.

Hybrid Imaging PET/CT with Application of 18F-Fluorothymidine in Patients with Head and Neck Carcinoma Undergoing Radiotherapy.

Baxa J, Ferda J, Ferdova E, Vojtisek R, Topolcan O, Finek J.

Anticancer Res. 2018 Jul;38(7):4153-4157. doi: 10.21873/anticanres.12708.

PMID:
29970544
14.

Low-dose High-resolution 18F-FDG-PET/CT Using Time-of-flight and Point-spread Function Reconstructions: A Role in the Detection of Breast Carcinoma Axillary Lymph Node Metastases.

Ferdová E, Baxa J, Ňaršanská A, Hes O, Fínek J, Topolčan O, Ferda J.

Anticancer Res. 2018 Jul;38(7):4145-4148. doi: 10.21873/anticanres.12706.

PMID:
29970542
15.

18F-Fluorocholine PET/MRI in Restaging of Prostatic Carcinoma in Relation to PSA Level and Detection of Active Disease.

Ferda J, Ferdová E, Baxa J, Fínek J, Topolčan O.

Anticancer Res. 2018 Jul;38(7):4139-4143. doi: 10.21873/anticanres.12705.

PMID:
29970541
16.

Perioperative Tumour Marker Levels as Prognostic Factors for Surgical Treatment of Breast Cancer Liver Metastases.

Treska V, Topolcan O, Zoubkova V, Treskova I, Narsanska A, Kucera R.

Anticancer Res. 2018 Jun;38(6):3647-3652. doi: 10.21873/anticanres.12640.

PMID:
29848722
17.

Follicular fluid levels of anti-Müllerian hormone, insulin-like growth factor 1 and leptin in women with fertility disorders.

Kucera R, Babuska V, Ulcova-Gallova Z, Kulda V, Topolcan O.

Syst Biol Reprod Med. 2018 Jun;64(3):220-223. doi: 10.1080/19396368.2018.1450906. Epub 2018 Mar 29.

PMID:
29595066
18.

[One-Step Nucleic Acid Amplification method - what is the future of sentinel lymph node management?]

Kosťun J, Pešta M, Slunečko R, Vlasák P, Bouda J, Berezovskiy D, Topolčan O, Novotný Z, Presl J.

Ceska Gynekol. Winter 2018;83(1):57-61. Czech.

PMID:
29510642
20.

CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer.

Svobodova S, Kucera R, Fiala O, Karlikova M, Narsanska A, Zedníková I, Treska V, Slouka D, Rousarova M, Topolcan O, Finek J.

Anticancer Res. 2018 Jan;38(1):465-469.

PMID:
29277810
21.

A more sensitive detection of micrometastases of NSCLC in lymph nodes using the one-step nucleic acid amplification (OSNA) method.

Vodicka J, Mukensnabl P, Vejvodova S, Spidlen V, Kulda V, Topolcan O, Pesta M.

J Surg Oncol. 2018 Feb;117(2):163-170. doi: 10.1002/jso.24826. Epub 2017 Dec 4.

PMID:
29205350
22.

Predictive Significance of Thymidylate Synthase Expression in Non-small Cell Lung Cancer.

Kulda V, Hrda K, Houdek Z, Dobra JK, Vrzakova R, Svaton M, Safranek J, Dolezal J, Babuska V, Pesek M, Topolcan O, Pesta M.

Anticancer Res. 2017 Dec;37(12):6953-6958.

PMID:
29187479
23.

Serum Vitamin D Status, Vitamin D Receptor Polymorphism, and Glucose Homeostasis in Healthy Subjects.

Mayer O, Seidlerová J, Černá V, Kučerová A, Karnosová P, Hronová M, Wohlfahrt P, Fuchsová R, Filipovský J, Cífková R, Topolčan O, Pešta M.

Horm Metab Res. 2018 Jan;50(1):56-64. doi: 10.1055/s-0043-122144. Epub 2017 Nov 28.

PMID:
29183090
24.

Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC.

Fiala O, Hosek P, Pesek M, Finek J, Racek J, Stehlik P, Sorejs O, Minarik M, Benesova L, Celer A, Nemcova I, Kucera R, Topolcan O.

Anticancer Res. 2017 Nov;37(11):6469-6476.

PMID:
29061834
25.

The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab.

Fiala O, Pitule P, Hosek P, Liska V, Sorejs O, Bruha J, Vycital O, Buchler T, Poprach A, Topolcan O, Finek J.

Tumour Biol. 2017 Jul;39(7):1010428317709283. doi: 10.1177/1010428317709283.

PMID:
28714375
26.

Serum Levels of IGF-1 and IGFBP-3 in Relation to Clinical and Pathobiological Aspects of Head and Neck Squamous Cell Carcinomas.

Kalfert D, Ludvikova M, Topolcan O, Celakovsky P, Kucera R, Windrichova J, Ludvik J, Skalova K, Kulda V, Pesta M, Plzak J.

Anticancer Res. 2017 Jun;37(6):3281-3286.

PMID:
28551677
27.

Synergistic effect of low K and D vitamin status on arterial stiffness in a general population.

Mayer O Jr, Seidlerová J, Wohlfahrt P, Filipovský J, Cífková R, Černá V, Kučerová A, Pešta M, Fuchsová R, Topolčan O, Jardon KMC, Drummen NEA, Vermeer C.

J Nutr Biochem. 2017 Aug;46:83-89. doi: 10.1016/j.jnutbio.2017.04.010. Epub 2017 Apr 22.

PMID:
28486172
28.

Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed.

Fiala O, Hosek P, Pesek M, Finek J, Racek J, Buchler T, Poprach A, Hejduk K, Chloupkova R, Sorejs O, Ecksteinova M, Vitovec M, Cizkova K, Kucera R, Topolcan O.

Neoplasma. 2017;64(4):605-610. doi: 10.4149/neo_2017_416.

PMID:
28485168
29.

Importance of Preoperative Knowledge of the Biomarker HE4 in Early-stage Endometrial Cancer Regarding Surgical Management.

Presl J, Ovesna P, Novotny Z, Vlasak P, Bouda J, Kostun J, Topolcan O, Kucera R, Bednarikova M, Weinberger V.

Anticancer Res. 2017 May;37(5):2697-2702.

PMID:
28476847
30.

Evaluation of Tumor Markers and Their Impact on Prognosis in Gallbladder, Bile Duct and Cholangiocellular Carcinomas - A Pilot Study.

Liska V, Treska V, Skalicky T, Fichtl J, Bruha J, Vycital O, Topolcan O, Palek R, Rosendorf J, Polivka J, Holubec L.

Anticancer Res. 2017 Apr;37(4):2003-2009.

PMID:
28373474
31.

The effect of meal frequency in a reduced-energy regimen on the gastrointestinal and appetite hormones in patients with type 2 diabetes: A randomised crossover study.

Belinova L, Kahleova H, Malinska H, Topolcan O, Windrichova J, Oliyarnyk O, Kazdova L, Hill M, Pelikanova T.

PLoS One. 2017 Apr 3;12(4):e0174820. doi: 10.1371/journal.pone.0174820. eCollection 2017.

32.

MIC1/GDF15 as a Bone Metastatic Disease Biomarker.

Windrichova J, Fuchsova R, Kucera R, Topolcan O, Fiala O, Finek J, Slipkova D.

Anticancer Res. 2017 Mar;37(3):1501-1505.

PMID:
28314325
33.

Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.

Fiala O, Pesek M, Skrickova J, Kolek V, Salajka F, Tomiskova M, Satankova M, Kultan J, Kuliskova J, Svaton M, Hrnciarik M, Hejduk K, Chloupkova R, Topolcan O, Hornychova H, Nova M, Ryska A, Finek J.

Tumour Biol. 2017 Feb;39(2):1010428317691186. doi: 10.1177/1010428317691186.

PMID:
28218046
34.

Changes in the expression of N- and O-glycopeptides in patients with colorectal cancer and hepatocellular carcinoma quantified by full-MS scan FT-ICR and multiple reaction monitoring.

Darebna P, Novak P, Kucera R, Topolcan O, Sanda M, Goldman R, Pompach P.

J Proteomics. 2017 Feb 5;153:44-52. doi: 10.1016/j.jprot.2016.09.004. Epub 2016 Sep 16.

35.

Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.

Kulda V, Topolcan O, Kucera R, Kripnerova M, Srbecka K, Hora M, Hes O, Klecka J, Babuska V, Rousarova M, Benson V, Pesta M.

Anticancer Res. 2016 Sep;36(9):4787-93.

PMID:
27630329
36.

Circulating Growth and Angiogenic Factors and Lymph Node Status in Early-stage Breast Cancer - A Pilot Study.

Karlikova M, Topolcan O, Narsanska A, Kucera R, Treskova I, Treska V.

Anticancer Res. 2016 Aug;36(8):4209-14.

PMID:
27466533
37.

Current status of biomarker research in neurology.

Polivka J, Polivka J Jr, Krakorova K, Peterka M, Topolcan O.

EPMA J. 2016 Jul 4;7:14. doi: 10.1186/s13167-016-0063-5. eCollection 2016. Review.

38.

[Biobanks European infrastructure].

Kinkorová J, Topolčan O.

Cas Lek Cesk. 2016;155(3):44-6. Review. Czech.

PMID:
27256149
39.

Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib.

Fiala O, Pesek M, Finek J, Topolcan O, Racek J, Svaton M, Kucera R, Minarik M, Benesova L, Bortlicek Z, Chloupkova R, Poprach A, Buchler T.

Anticancer Res. 2016 May;36(5):2459-65.

PMID:
27127158
40.

Anti-Müllerian hormone in serum and seminal plasma in comparison with other male fertility parameters.

Kucera R, Ulcova-Gallova Z, Windrichova J, Losan P, Topolcan O.

Syst Biol Reprod Med. 2016 Jun;62(3):223-6. doi: 10.3109/19396368.2016.1161864. Epub 2016 Apr 25.

PMID:
27110929
41.

Tissue microRNAs as predictive markers for gastric cancer patients undergoing palliative chemotherapy.

Smid D, Kulda V, Srbecka K, Kubackova D, Dolezal J, Daum O, Kucera R, Topolcan O, Treska V, Skalicky T, Pesta M.

Int J Oncol. 2016 Jun;48(6):2693-703. doi: 10.3892/ijo.2016.3484. Epub 2016 Apr 12.

PMID:
27081844
42.

Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.

Windrichova J, Fuchsova R, Kucera R, Topolcan O, Fiala O, Finek J, Slipkova D, Karlikova M, Svobodova J.

Anticancer Res. 2016 Apr;36(4):1973-8.

PMID:
27069189
43.

Searching for New Biomarkers and the Use of Multivariate Analysis in Gastric Cancer Diagnostics.

Kucera R, Smid D, Topolcan O, Karlikova M, Fiala O, Slouka D, Skalicky T, Treska V, Kulda V, Simanek V, Safanda M, Pesta M.

Anticancer Res. 2016 Apr;36(4):1967-71.

PMID:
27069188
44.

Predictive Value of Growth Factors and Interleukins for Future Liver Remnant Volume and Colorectal Liver Metastasis Volume Growth Following Portal Vein Embolization and Autologous Stem Cell Application.

Fichtl J, Treska V, Lysak D, Mirka H, Duras P, Karlikova M, Skalicky T, Vodička J, Topolcan O.

Anticancer Res. 2016 Apr;36(4):1901-7.

PMID:
27069178
45.

The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.

Svaton M, Fiala O, Pesek M, Bortlicek Z, Minarik M, Benesova L, Topolcan O.

Anticancer Res. 2016 Mar;36(3):1077-82.

PMID:
26977001
46.

Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib.

Fiala O, Pesek M, Finek J, Racek J, Minarik M, Benesova L, Bortlicek Z, Sorejs O, Kucera R, Topolcan O.

Neoplasma. 2016;63(3):471-6. doi: 10.4149/318_151001N512.

PMID:
26952513
47.

Effects of Icodextrin and Glucose Bicarbonate/Lactate-Buffered Peritoneal Dialysis Fluids on Effluent Cell Population and Biocompatibility Markers IL-6 and CA125 in Incident Peritoneal Dialysis Patients.

Opatrná S, Pöpperlová A, Lysák D, Fuchsová R, Trefil L, Racek J, Topolčan O.

Ther Apher Dial. 2016 Apr;20(2):149-57. doi: 10.1111/1744-9987.12391. Epub 2016 Mar 1.

PMID:
26929256
48.

The Role of TPS and TPA in the Diagnostics of Distant Metastases.

Kucera R, Topolcan O, Fiala O, Kinkorova J, Treska V, Zedníková I, Slouka D, Simanek V, Safanda M, Babuska V.

Anticancer Res. 2016 Feb;36(2):773-7.

PMID:
26851038
49.

Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma.

Polivka J Jr, Polivka J, Repik T, Rohan V, Hes O, Topolcan O.

Anticancer Res. 2016 Jan;36(1):471-6.

PMID:
26722084
50.

Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy.

Fiala O, Pesek M, Finek J, Svaton M, Sorejs O, Bortlicek Z, Kucera R, Topolcan O.

Anticancer Res. 2016 Jan;36(1):461-6.

PMID:
26722082

Supplemental Content

Loading ...
Support Center